Back to results
US 2021/0267947 A1Published application
Triazole benzamide derivatives as gpr142 agonists
AssigneeBoehringer Ingelheim International GmbH
InventorsArmin HECKEL, Robert AUGUSTIN, Sebastian BANDHOLTZ, Sara FRATTINI, Bernd WELLENZOHN
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, R4, n and m are as defined herein, which have valuable pharmacological properties, in particular bind to the GPR142 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as type 2 diabetes.
Claims15
A compound of formula (I)
- wherein
- R1 is selected from the group consisting of F, Cl, Br, I, CN, NO2, C1-3-alkyl, —O—(C1-4-alkyl), —COOH, —C(═O)—O—(C1-4-alkyl), —NH2, —NH(C1-3-alkyl) and —N(C1-3-alkyl)2,
- wherein each alkyl group or sub-group is optionally substituted with 1 or more F atoms;
- and
- wherein multiple R1 may be identical or different if n is 2;
- R2 is selected from the group consisting of H and C1-3-alkyl;
- R3 is C1-3-alkyl;
- R4 is C1-3-alkyl;
- n is an integer selected from 1 and 2;
- and
- m is an integer selected from 0 and 1;
- wherein in any definition mentioned hereinbefore, if not specified otherwise, any alkyl group or sub-group may be straight-chained or branched and is optionally substituted with 1 or more F atoms,
- or a salt thereof.
10 more elements
(canceled)
Dependencies are inferred from the claim text.